No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The label requires no change to dutasteride dosing for renal impairment. Limits and monitoring This finding concerns the single-ingredient oral capsule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 5, posted Nov 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding For adult nonvalvular AF, do not use edoxaban above CrCl 95 mL/min. Give 60 mg once daily at CrCl above 50 through 95, or 30 mg once daily at 15-50 mL/min. Use below 15 is not recommended. Limits and monitoring The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 28, posted Jul 14, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal pharmacokinetic studies are lacking. The small fraction of efavirenz eliminated unchanged in urine suggests little direct renal effect on elimination. Limits and monitoring This single-ingredient finding does not establish dosing for combination tablets or dialysis. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 2, posted Mar 01, 2013 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently. Limits and monitoring Use individually selected components if renal adjustment is necessary. Verify all active ingredients. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 6, posted Feb 12, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The elbasvir/grazoprevir dose does not change in renal impairment or hemodialysis. If ribavirin is required and CrCl is 50 mL/min or lower, use ribavirin-specific dosing. Limits and monitoring Confirm HCV genotype, indication and hepatic eligibility for the combination. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 22, posted Mar 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Elotuzumab disposition was similar across the studied renal categories, including ESRD with and without hemodialysis. Limits and monitoring The pharmacokinetic analysis supplies no instruction to give a supplemental postdialysis dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Jun 28, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Do not initiate Stribild if estimated CrCl is below 70 mL/min. Discontinue it if estimated CrCl falls below 50 mL/min during treatment. Limits and monitoring The fixed tablet contains tenofovir disoproxil fumarate. Confirm the product and monitor renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 22, posted Feb 14, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The product has not been studied in severe renal impairment. Limits and monitoring The cited evidence supplies no severe-impairment or dialysis dose recommendation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 17, posted Jul 21, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding Do not start this metformin-containing ER combination below eGFR 45 mL/min/1.73 m2. It is contraindicated below 30. Limits and monitoring Starting, continuing, and interruption for iodinated contrast have separate label instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Aug 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30 mL/min or less, start IV enalaprilat at 0.625 mg. The usual IV dose at clearance above 30 is 1.25 mg every six hours. Limits and monitoring Reassess pressure and renal response after the initial dose. Oral conversion has separate instructions. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 1, posted Mar 13, 2008 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For adult hypertension with CrCl 30 mL/min or less, the recommended first oral enalapril dose is 2.5 mg once daily. Above 30, the usual initial regimen applies. Limits and monitoring Dialysis days, heart failure, baseline hypotension and diuretic use have separate considerations. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Jan 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For adult CrCl below 30 mL/min, labeled abdominal surgery, hip/knee replacement, and acutely ill medical prophylaxis use 30 mg SC daily. Labeled DVT treatment with warfarin uses 1 mg/kg SC daily. Limits and monitoring ACS and STEMI have indication- and age-specific instructions. Assess bleeding and neuraxial procedure timing separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 33, posted May 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
